Experimental prostate cancer drug shows promise. CryoLife Post Record Revenue. Print E-mail
By BioMedReports.com Staff   
Thursday, 17 February 2011 19:39
Below is a look at some of the headlines for companies that made news in the healthcare sector on February 17, 2011.

Exelixis Inc's (NASDAQ:EXEL) experimental cancer drug Cabozantinib shows in a mid-stage trial to completely or partially clear up bone lesions from prostate cancer in 85 percent of patients.  The First of three Phase 3 trials to start 2nd half 2012.  In addition the tumors shrank 61 of the 91 patients with cancer which had spread to some soft tissues including the lungs and liver.  With this information shares of Exelixis rose up to 4 percent.  

Results for the fourth quarter and the full year of 2010, show CryoLife, Inc. (NYSE:CRY), an implantable biological medical device and cardiovascular tissue processing company, had another record in annual revenues and operating cash flow increasing 2010 cash flow to $20.8 million.  The Company recorded pretax charges in the fourth quarter of 2010 of approximately $474,000 related to business development activities and $268,000 related to litigation with Medafor.  Revenues for the full year of 2010 increased 4 percent to a record $116.6 million compared to $111.7 million for 2009.


Earlier Thursday:

Boston Scientific Corporation (NYSE:BSX) today announced its launch of the PROMUS® Element™ Everolimus-Eluting Coronary Stent System and TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System in India.  

CytoSorbents Corporation (OTCBB:CTSO), a critical care focused company using blood purification to treat life-threatening illnesses, announced the issuance of two additional U.S. patents, bringing its total patent portfolio to 29 issued patents.

Delcath Systems, Inc. (Nasdaq:DCTH) today announced that the Company has achieved ISO 13485:2003 Certification—an internationally recognized quality standard designed to ensure that medical device manufacturers have the necessary comprehensive management systems in place to safely design, develop, manufacture and distribute medical devices in the European Union (EU).

GeckoSystems Intl. Corp. (PINKSHEETS:GOSY), a dynamic leader in the development and usage of "Mobile Robot Solutions for Safety, Security and Service"™ for the emerging mobile robotics industry, reported today its board of directors recently authorized a 40,000,000 share buy back representing more than 7 percent of the present number of issued and outstanding shares.

Healthnostics, Inc. (PINKSHEETS: HNS) has initiated operations under its joint venture with U.S. News Marketing Co., a division of U.S. News Co.

Nektar Therapeutics (Nasdaq:NKTR) will announce its financial results for the fourth quarter ended December 31, 2010 on Tuesday, March 1, 2011, after the close of U.S.-based financial markets.

TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for the treatment of cancer and other diseases, today announced that it has shipped its 350th treatment system.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter